{
    "nct_id": "NCT04011410",
    "official_title": "Phase 2 Study of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer",
    "inclusion_criteria": "* Histologically confirmed prostate cancer that has recurred\n* Three or fewer synchronous metastatic lesions (on imaging) with no evidence of residual local disease\n* ECOG performance status 0 - 2\n* Approval by screening eye exam (disqualifying baseline conditions listed below)\n* Ability to provide informed consent\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receipt of hydroxychloroquine (HCQ) within the past 6 months\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ\n* Use of contraindicated medications,\n* Macular degeneration\n* Cataracts\n* Severe baseline visual impairment, retinopathy or visual field changes\n* Presence of only one functional eye\n* Prior treatment with ADT including:\n* Previous history of radiation or surgery to a metastatic site\n* Serum testosterone less than 50 ng/ml\n* History of orchiectomy\n* History of pathologic fracture or spinal cord compression\n* Brain or CNS metastases\n* History of G-6-PD (glucose-6-phosphate dehydrogenase) deficiency\n* Uncontrolled intercurrent illness\n* Psychiatric illness and/or social situations that would limit compliance with study requirements.\n* Patients taking other investigational agents",
    "miscellaneous_criteria": ""
}